A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Phase 2 Completed 125 enrolled Novo Nordisk A/S

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as injections under the skin

Timeline

Start: 2023-09-15
Primary completion: 2024-11-27
Completion: 2024-11-27

Publications

Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, Heydorn A, Jastreboff AM, Key C, Petersen SB, Vegge A, Adelborg K. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025 Jul 12;406(10499):149-162. doi: 10.1016/S0140-6736(25)01185-7. Epub 2025 Jun 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NNC0487-0111	Unknown	1.25 mg	Subcutaneous
Subject	NNC0487-0111	Unknown	5 mg	Subcutaneous
Subject	NNC0487-0111	Unknown	20 mg	Subcutaneous
Subject	NNC0487-0111	Unknown	60 mg	Subcutaneous

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Summary

Timeline

Publications

Drugs

Indications